McKesson (NYSE:MCK) Stock Gets Price Target Boost from UBS Group

McKesson (NYSE:MCK) had its target price boosted by investment analysts at UBS Group from $1,200.00 to $1,250.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. UBS Group‘s price target would indicate a potential upside of 17.84% from the company’s previous close.

Other research analysts also recently issued reports about the company. Royal Bank Of Canada lifted their price target on McKesson from $845.00 to $965.00 and gave the company a “sector perform” rating in a report on Thursday. Morgan Stanley set a $977.00 price objective on shares of McKesson in a research report on Tuesday, October 6th. Wells Fargo & Company boosted their price objective on shares of McKesson from $812.00 to $933.00 and gave the stock an “equal weight” rating in a research note on Tuesday, August 11th. Mizuho increased their target price on shares of McKesson from $905.00 to $1,020.00 and gave the company a “neutral” rating in a research report on Tuesday, October 20th. Finally, Weiss Ratings upgraded shares of McKesson from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, September 4th. Fifteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $1,026.18.

McKesson Stock Performance

McKesson stock traded down $11.21 during trading hours on Thursday, hitting $1,060.79. The company had a trading volume of 812,129 shares, compared to its average volume of 691,239. The firm has a market cap of $123.68 billion, a P/E ratio of 27.28, a P/E/G ratio of 1.99 and a beta of 0.27. The company has a 50-day moving average price of $938.13 and a two-hundred day moving average price of $868.12. McKesson has a 1 year low of $723.68 and a 1 year high of $1,121.50.

McKesson (NYSE:MCK) last announced its quarterly earnings data on Wednesday, November 4th. The company reported $11.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.72 by $0.96. McKesson had a negative return on equity of 253.21% and a net margin of 1.12%. The company had revenue of $110.96 billion for the quarter, compared to analysts’ expectations of $109.90 billion. During the same quarter in the prior year, the firm earned $9.86 earnings per share. McKesson’s revenue was up 7.5% compared to the same quarter last year. As a group, equities research analysts anticipate that McKesson will post 45.26 EPS for the current year.

Insider Activity at McKesson

In related news, Director Bradley Lerman sold 301 shares of McKesson stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $892.33, for a total value of $268,591.33. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO B Jr sold 111 shares of the business’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $891.45, for a total transaction of $98,950.95. Following the sale, the chief accounting officer directly owned 521 shares in the company, valued at approximately $464,445.45. This represents a 17.56% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 2,462 shares of company stock valued at $2,511,106 in the last three months. 0.06% of the stock is owned by insiders.

Institutional Trading of McKesson

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Secure Asset Management LLC lifted its holdings in shares of McKesson by 484.8% in the 2nd quarter. Secure Asset Management LLC now owns 2,123 shares of the company’s stock valued at $1,604,000 after buying an additional 1,760 shares during the period. BayBridge Capital Group LLC boosted its stake in shares of McKesson by 268.0% in the second quarter. BayBridge Capital Group LLC now owns 1,943 shares of the company’s stock worth $1,468,000 after buying an additional 1,415 shares during the last quarter. Royal London Asset Management Ltd. grew its holdings in McKesson by 1.1% during the second quarter. Royal London Asset Management Ltd. now owns 112,241 shares of the company’s stock worth $84,809,000 after acquiring an additional 1,216 shares during the period. Benchmark Investment Advisors LLC acquired a new stake in McKesson during the second quarter worth about $441,000. Finally, One Wealth Advisors LLC purchased a new position in McKesson during the second quarter valued at approximately $1,494,000. Institutional investors and hedge funds own 85.07% of the company’s stock.

Trending Headlines about McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson beat fiscal Q2 2027 estimates, reporting adjusted EPS of $11.68 and revenue of about $111 billion, up roughly 7.5% year over year. The company also raised its fiscal 2027 adjusted EPS outlook to $45.60–$46.40, supported by specialty-drug demand, higher prescription volumes and operating gains. MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
• Positive Sentiment: Analyst sentiment has strengthened: UBS raised its price target to $1,250 and maintained a Buy rating, while TD Cowen and Leerink Partners lifted targets to $1,200. Separately, Zacks upgraded MCK to Rank #2 (Buy), citing improving earnings prospects. Zacks upgrades McKesson to Buy
• Neutral Sentiment: EVP Francisco Fraga sold 650 shares under a pre-arranged Rule 10b5-1 plan and retained 4,414 shares. The filing does not explain the purpose of this latest sale; an earlier sale was described as covering tax withholding on vested equity awards. SEC filing
• Negative Sentiment: RBC raised its price target but kept a Sector Perform rating and set a $965 target, below the recent share price. That more cautious view may temper enthusiasm after MCK’s strong run. RBC comments on McKesson’s execution

About McKesson

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and other medical products. Its customers include pharmacies, hospitals, health systems, clinics and other healthcare providers.

The company also provides medical-surgical supplies and technology and services that support pharmacy operations, prescription management and care delivery. Its offerings include specialized support for oncology and other areas of care.

Founded in 1833, McKesson serves customers primarily in the United States and Canada.